Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service

Anteris Provides Update on DurAVRtm THV Valve-in-Valve Experience Presented at New York Valves 2024

Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVRtm THV, a new class of TAVR and the world's only balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, today announced a summation of the Company's presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.

Dr Anita Asgar, Institut de Cardiologie de Montreal, presented a series of cases from five high-risk patients who underwent valve-in-valve (ViV) procedures using DurAVRtm THV. The patients were treated under Health Canada's special access program (SAP) which allows health care professionals to access unlicensed medical devices, such as DurAVRtm, for emergency use when conventional therapies have failed, are unavailable, or are unsuitable to treat a patient.

Unique Challenges of ViV Procedures

While TAVR procedures have revolutionized heart valve replacement, up to 30% of patients may eventually require a second valve due to deterioration of the first implant1. Transcatheter ViV replacement is performed by implanting a transcatheter heart valve within a failing bioprosthetic aortic valve. The transcatheter ViV operation is a less invasive procedure compared with reoperative surgical aortic valve replacement however this repeat procedure presents unique challenges for both doctors and patients.

"Valve-in-valve procedures often force us to make difficult choices," explained Dr. Asgar. "Current TAVR devices may limit optimal valve function (hemodynamics) for these very sick patients, while others are operationally challenging to ensure access to coronary arteries."

Restoring Valve Hemodynamics with DurAVRtm

ViV implantation with DurAVRtm THV successfully reduced aortic valve gradients to a level similar to the initial post-surgical valve gradient.

Average aortic valve gradients across the series of 5 cases:

No major complications were reported.

Dr Asgar commented "This data set of valve-in-valve patients highlights the impact of the DurAVRtm valve biomimetic design by restoring these patients' hemodynamics to the performance of their initial surgical valve and is very encouraging for the wave of valve-in-valve patients that are coming in the future."

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd (ASX: AVR) is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedTech hub), Anteris is science-driven, with an experienced team of multidisciplinary professionals delivering transformative solutions to structural heart disease patients.

The Company's lead product, DurAVRTM, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVRTM THV was designed in partnership with the world's leading interventional cardiologists and cardiac surgeons. It is the first transcatheter aortic valve replacement (TAVR) to use a single piece of bioengineered tissue. This biomimetic valve is uniquely shaped to mimic the performance of a healthy human aortic valve.

DurAVRTM THV is made using ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide.

The ComASURTM Delivery System was designed to provide controlled deployment and accurate placement of the DurAVRTM THV with balloon-expandable delivery, allowing precise alignment with the heart's native commissures to achieve optimal valve positioning.

Anteris Technologies is set to revolutionise the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.

Authorisation and Additional information

This announcement was authorised by Mr. Wayne Paterson, Chief Executive Officer.

  1. Giordana, F., Bruno, F., Controtto, F. et al. Incidence, predictors and outcomes of valve-in-valve TAVI: A systematic review and meta-analysis. Int. J. Cardiol. 316 (2020). https://doi.org/10.1016/j.ijcard.2020.05.058

These press releases may also interest you

at 10:07
Designed in Boulder, Colorado, USA, the SparkFun RTK EVK (Evaluation Kit) is the perfect development platform for your fixed or mobile high-precision positioning and navigation needs. In terms of connectivity options, the SparkFun RTK EVK has the...

at 10:05
Insurance companies in North America are upgrading systems and adopting advanced technologies to overcome the limitations of decades-old IT platforms, according to a new research report published today by Information Services Group (ISG) , a leading...

at 10:05
GlassHive, a trailblazer in sales and marketing automation, has announced an integration with ConnectWise, a leading provider of business automation software for Managed Service Providers (MSPs), to deliver sales and marketing automation through the...

at 10:05
Stellar Market Research, a leading Healthcare business research firm has published a report on the "PPG Biosensors Market". The market size for the PPG Biosensors Market was USD 470.49 Mn in 2023 and is expected to grow at a CAGR of 11.4 percent...

at 10:02
The global security brokerage and stock exchange services market size is estimated to grow by USD 801.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.45% during the forecast period. Increasing demand...

at 10:01
The global Hydrogen Technology Testing, Inspection and Certification (TIC) Market is valued at USD 4.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029; it is expected to register a CAGR of 17.8% during the forecast period according...

News published on and distributed by: